Evidence Intelligence™
- ImpactScore™
- 76
- Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
Add to Evidence TrackerResumen de Investigación
Analyzed using Evidence Intelligence™
Liraglutide shows no effect on plasma GDF15 levels
Última actualización 4 de julio de 2026
Key finding
Liraglutide treatment decreased body weight significantly.
This study investigated the effects of liraglutide on plasma GDF15 levels in patients with type 2 diabetes, finding no significant changes in GDF15 levels.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda este estudio en tu Evidence Tracker para encontrarlo facilmente cuando lo necesites.
Plain-language summary
What this paper says
A plain-language read of the study's main message and where it applies.
Study focus
This study investigated the effects of liraglutide on plasma GDF15 levels in patients with type 2 diabetes, finding no significant changes in GDF15 levels.
Clinical relevance
Understanding the effects of liraglutide on weight and biomarkers like GDF15 is crucial for diabetes management. While weight loss is beneficial for patients with type 2 diabetes, the lack of effect on GDF15 levels suggests that liraglutide may not influence this particular biomarker, which could have implications for understanding its overall metabolic effects.
Keep in mind
The study did not assess long-term effects of liraglutide on GDF15 levels. Sample size and population characteristics may limit generalizability. The effectiveness of liraglutide on other metabolic parameters was not evaluated.
Published in
Referencia de la Revista
Publication details and source links for this paper.
Carlijn AH, Maaike ES, Maurice BB, et al. Liraglutide treatment does not modify plasma GDF15 levels in patients with type 2 diabetes. Experimental Physiology. 2024;109(8):1292-1304. doi:10.1113/EP091815
Efectos Principales
Liraglutide treatment resulted in a significant decrease in body weight by 4.5 kg (p=0.01).
Liraglutide did not modify plasma GDF15 levels in any patients.
Placebo treatment also did not affect plasma GDF15 levels.
Evidence network
How this study fits
Understand where this research contributes within the broader evidence network.
Evidence Context
This study contributes evidence to Liraglutide and Body weight, Growth differentiation factor 15.
This study contributes evidence to
Primary intervention
Liraglutide
Primary outcomes
- Body weight
- Growth differentiation factor 15
Evidence topics
Primary intervention
Primary outcomes
Evidence relationships
Intervention and outcome relationships this study adds to the evidence network.
2
Evidence pairs
2
Relationships
3
Evidence topics
contributes_evidence
Editorial context
Why this study matters
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
Moderate contributionModerate confidenceNetwork score: 60
3
Related topics
2
Evidence pairs
163
Related studies
High relevance in at least one topic
Why it is useful
- Contributes to 2 evidence relationships
- Includes primary outcome data
- Linked to 3 direct semantic evidence topics
Topic contributions
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Agrega evidencia relacionada a tu Evidence Tracker
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
GLP-1 Receptor Agonists and Body Weight
Evidencia relacionada
Relación de evidencia
GLP-1 Receptor Agonists and Inflammatory Markers
Seguir evidencia
Tema de evidencia
Weight Loss
Seguir evidencia
Core evidence
Study findings
The primary outcomes reported in this study.
Growth differentiation factor 15
Liraglutide → Growth differentiation factor 15
Liraglutide → Growth differentiation factor 15
Evidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
Add to Evidence TrackerBuild your personal Evidence Workspace
Create a free account to save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
La Evidencia Sugiere
- Liraglutide led to a weight reduction of 4.5 kg (p=0.01).
- No change in plasma GDF15 levels was observed with liraglutide.
- Placebo also showed no effect on GDF15 levels.
A quién se aplica
- Adults diagnosed with type 2 diabetes.
- Patients undergoing treatment with liraglutide.
Tener en Cuenta
- The study focused solely on the effects of liraglutide and did not explore other treatments.
- Findings may not apply to populations outside the study's sample.
- The lack of effect on GDF15 levels suggests further research is needed to understand liraglutide's mechanisms.
Entre Líneas
- The study did not assess long-term effects of liraglutide on GDF15 levels.
- Sample size and population characteristics may limit generalizability.
- The effectiveness of liraglutide on other metabolic parameters was not evaluated.
Save this study
Keep this study in your Evidence Tracker so you can easily find it again whenever you need it.
Today's Activity
Your Evidence Workspace
Saved this study
Your free account becomes your personal diabetes evidence workspace.
Evidence Tracker
12 tracked topics
Saved Studies
48 studies
Research Notes
Coming Soon
Weekly Evidence Digest
Coming Soon
Already have an account?
Connected Evidence
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Body Weight, GLP-1 Receptor Agonists and Inflammatory Markers.
Relaciones de evidencia relacionadas
Explore in Evidence ArchiveThis study contributes to the evidence on the following intervention-outcome relationships.
Medications
Detailed evidenceGLP-1 Receptor Agonists → Body Weight
Medications
Evidence Intelligence™
- ImpactScore™
- 76
- Positive
- EvidenceScore™
- Strong
- Score 79 · Based on 4 studies
- ConsistencyScore™
- 100
- consistent
Supporting studies: Based on 4 studies
View evidenceMedications
Detailed evidenceEvidence Intelligence™
- ImpactScore™
- 50
- Neutral
- EvidenceScore™
- Emerging
- Score 59 · Based on 1 study
- ConsistencyScore™
- unclear
- Not enough independent studies
Supporting studies: Based on 1 study
View evidenceIncluido en estas colecciones de evidencia
Curated evidence collections and hubs this study is part of.
Body Weight Evidence Hub
All studies measuring Body Weight
4 studies
outcome_hubMeasures Body Weight as a key outcome.
GLP-1 Receptor Agonists Evidence Hub
All studies on GLP-1 Receptor Agonists
4 studies
intervention_hubContributes to GLP-1 Receptor Agonists evidence base.
Inflammatory Markers Evidence Hub
All studies measuring Inflammatory Markers
1 studies
outcome_hubMeasures Inflammatory Markers as a key outcome.
Recent Diabetes Research
Latest published studies
recency_collection
Published within the last 2 years.
Explora más en el archivo de evidencia
Jump to pre-filtered views in the evidence archive.
All studies on Liraglutide and Body weight
Intervention: LiraglutideOutcome: Body weight
4 results
All studies on Liraglutide and Growth differentiation factor 15
Intervention: LiraglutideOutcome: Growth differentiation factor 15
1 results
All studies on Liraglutide
Intervention: Liraglutide
4 results
All studies measuring Body weight
Outcome: Body weight
4 results
All studies measuring Growth differentiation factor 15
Outcome: Growth differentiation factor 15
1 results
Questions answered by this study
Generated from the study's connected evidence using Evidence Intelligence™.
Does GLP-1 Receptor Agonists affect body weight?
Strong Evidence
GLP-1 Receptor Agonists may improve Body Weight.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Body weight
EvidenceScore™ Strong | EvidenceScore™ 79.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 26 supporting studies with consistent results and a positive effect signal.
Limitations
- Population details are unavailable.
Does GLP-1 Receptor Agonists improve inflammatory markers?
Strong Evidence
Current evidence does not show a clear benefit of GLP-1 Receptor Agonists for Inflammatory Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
- 1
Growth differentiation factor 15
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 3 supporting studies and existing graph evidence signals.
Limitations
- Population details are unavailable.
Next steps
Continue your research
Choose a next path through related evidence topics, archive views, and research summaries.
Evidence topics
Follow the topics this study contributes to.
Explore in archive
Open broader archive views for this relationship.
Related research
Read related research summaries.
Liraglutide is well tolerated in diabetes patients undergoing hemodialysis.Liraglutide may reduce stroke recurrence in type 2 diabetes patientsLiraglutide 3 mg pathway improves weight loss.Liraglutide improves glycaemic control in adults with T2DNewer diabetes drugs show stronger weight and blood sugar benefits in prediabetes
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.